Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 4/20 | 0.53 |
| ▸ | CES2 | O00748 | 3/20 | 0.53 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.49 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.49 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.49 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234327 | 0.85 | CES2 (0.68) | TDP1ALDH1A1MAPTSRD5A2POLB | |
| SCHEMBL7785000 | 0.84 | CES2 (0.62) | ALDH1A1MAPTPOLBMAPK1LMNA | |
| SCHEMBL8962651 | 0.83 | CES2 (0.66) | TDP1ALDH1A1MAPTSRD5A2POLB | |
| SCHEMBL1642912 | 0.83 | SRD5A2 (0.69) | TDP1ALDH1A1MAPTSRD5A2POLB | |
| Benzophenone SCHEMBL28231509 | 0.81 | POLB (0.82) | TDP1ALDH1A1MAPTSRD5A2POLB | |
| SCHEMBL229627 | 0.81 | POLB (0.82) | TDP1ALDH1A1MAPTSRD5A2POLB | |
| SCHEMBL3038873 | 0.81 | CES2 (0.63) | TDP1ALDH1A1MAPTLMNAL3MBTL1 | |
| SCHEMBL975118 | 0.80 | SRD5A2 (0.83) | TDP1ALDH1A1MAPTSRD5A2POLB | |
| SCHEMBL10723714 | 0.80 | SRD5A2 (0.83) | TDP1ALDH1A1MAPTSRD5A2POLB | |
| SCHEMBL1258944 | 0.80 | CES2 (0.74) | TDP1POLBL3MBTL1CES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1901910-A | Substituted piperidine compounds for the treatment of metabolic syndrome | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | CN | claimed |
| CN-1901910-A | Substituted piperidine compounds for the treatment of metabolic syndrome | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | CN | disclosed |
| US-20050014788-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| EP-1448524-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003042177-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014788-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | CCR5, CCR2, CCL2 | TDP1 4439/4885ALDH1A1 954/4885MAPT 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.